ARMANDO ANIDO - 12 Sep 2023 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc. (ZYNE)

Role
Chairman & Chief Exec. Officer, Director
Signature
/s/ Albert P. Parker, Attorney-in-Fact
Issuer symbol
ZYNE
Transactions as of
12 Sep 2023
Transactions value $
-$23,637
Form type
4
Filing time
14 Sep 2023, 17:13:06 UTC
Previous filing
20 Jun 2023
Next filing
11 Oct 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYNE Common Stock Award +64.7K +7.28% 955K 12 Sep 2023 Direct F1
transaction ZYNE Common Stock Sale -$23.6K -17.8K -1.87% $1.33 937K 13 Sep 2023 Direct F2
holding ZYNE Common Stock 26.6K 12 Sep 2023 See footnote F3
holding ZYNE Common Stock 13.3K 12 Sep 2023 See footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On September 12, 2023, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 64,747 performance-based restricted stock awards granted in a prior year.
F2 This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
F3 TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to shares held by the trusts.